Highly effective antiangiogenesis via magnetic mesoporous silica-based siRNA vehicle targeting the VEGF gene for orthotopic ovarian cancer therapy.

摘要: Therapeutic antiangiogenesis strategies have demonstrated significant antitumor efficacy in ovarian cancer. Recently, RNA interference (RNAi) has come to be regarded as a promising technology for treatment of disease, especially In this study, vascular endothelial growth factor (VEGF)-small interfering (siRNA) was encapsulated into magnetic mesoporous silica nanoparticle (M-MSN)-based, polyethylenimine (PEI)-capped, polyethylene glycol (PEG)-grafted, fusogenic peptide (KALA)-functionalized siRNA delivery system, termed M-MSN_VEGF siRNA@PEI-PEG-KALA, which showed effectiveness with regard VEGF gene silencing vitro and vivo. The prepared system readily exhibited cellular internalization ease endosomal escape, resulting excellent RNAi without associated cytotoxicity SKOV3 cells. vivo experiments, notable retardation tumor observed orthotopic tumor-bearing mice, attributed inhibition angiogenesis by systemic administration nanocarrier. No obvious toxic drug responses were detected major organs. Further, the core siRNA@PEI-PEG-KALA proved capable probing site size cancer mice on resonance imaging. Collectively, results demonstrate that an M-MSN-based potential serve carrier therapeutics